What happened?

Shares of CRISPR Therapeutics (NASDAQ:CRSP) jumped by 13.8% on Monday, after the clinical-stage biotech company announced some exciting news regarding one of its leading pipeline candidate, CTX001. 

So what

CTX001 is an investigational treatment for Sickle Cell Disease (SCD) and transfusion-dependent beta-thalassemia (TDT), both of which are rare blood disorders. Today, CRISPR Therapeutics reported that the U.S. Food and Drug Administration (FDA) granted CTX001 the Regenerative Medicine Advanced Therapy (RMAT) designation. This designation is reserved for drugs or treatments that meet three criteria. 

Upward pointing arrows.

Image Source: Getty Images.

First, the drug must be a regenerative medicine therapy, a form of treatment that seeks to replace cells or tissues that are affected by a particular condition. Second, the treatment is intended to cure a severe or life-threatening disease. Third, "preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such disease or condition." 

In addition to the RMAT designation, the FDA granted CTX001 the orphan drug designation for TDT, while the European Medicines Agency (EMA) granted the treatment the orphan drug designation for both TDT and SCD.

Now what

In November 2019, CRISPR Therapeutics announced positive results from a phase 1/2 clinical trial for CTX001. The trial involved two patients, one with TDT and one with SCD. The TDT patient, who required 16.5 blood transfusions per year before the treatment, was transfusion-independent nine months after the treatment.

Meanwhile, four months after being treated with CTX001, the patient with SCD did not experience any vaso-occlusive crises (a side-effect of SCD that causes acute pain). Before the treatment, this patient experienced an average of seven vaso-occlusive crises per year. These results were encouraging, but investors should remember that there's still a long way to go before the biotech company can hope to launch CTX001 on the market. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.